Get the Stockscreener App
0.00
100.00%
-8.28
Cybin Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Cybin Inc., a biotechnology company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Cybin U.S., and Natures Journey. The Serenity Life and Cybin U.S. segment engages in the research and development of psychedelic pharmaceutical products. The Natures Journey segment focuses on non-psychedelic medicinal mushroom nutraceutical products. It develops CYB001, a drug candidate that is in phase IIa/b for major depressive disorder; CYB003, a deuterated tryptamine preclinical program to treat alcohol use disorder; CYB004, a deuterated tryptamine preclinical program for therapy resistant psychiatric disorder; and CYB005, a phenethylamine preclinical program for psychiatry and neurology. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada.
See More
Previous Close:
$8.28
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$413.12M
Revenue:
-
Net Income/Loss:
$-52.07M
P/E Ratio:
0.00
EPS:
-0.2077
Net Cash Flow:
$-44.93M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$8.40
52-Week Range:
$0.00
$10.73
Cybin Inc Stock (CYBN) Company Profile
Name
Cybin Inc
Sector
Industry
Phone
908 764 8385
Address
100 King Street West, Suite 5600, Toronto
Compare CYBN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYBN
Cybin Inc
|
0.00 | 413.12M | 0 | -52.07M | -44.93M | -0.2077 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cybin Inc Stock (CYBN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | Guggenheim | Buy |
| Nov-19-21 | Downgrade | Maxim Group | Buy → Hold |
Cybin Inc Stock (CYBN) Latest News
Helus Pharma rebrands, moves to Nasdaq as it advances late-stage mental health drugs - MSN
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq - bernama
(CYBN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Cybin (CYBN) Is Down 9.8% After Launching US$100M At-The-Market Equity ProgramWhat's Changed - simplywall.st
Helus Pharma Rebrands, Debuts On NasdaqBERNAMA - BERNAMA - Malaysian National News Agency
HELUS PHARMA REBRANDS, DEBUTS ON NASDAQ - bernama
Three new option listings and four option delistings on January 5th - TipRanks
What drives Cybin Inc R7E stock priceGlobal Market Influence & Explosive Growth Trading - earlytimes.in
Cybin to Begin Nasdaq Trading Under New Ticker, Plans to Change Name to Helus Pharma - marketscreener.com
Helus Pharma Rebrands, Moves to Nasdaq as It Advances Late-Stage Mental Health Drugs - TipRanks
Cybin (CYBN) Transitions to Helus Pharma and Moves to Nasdaq - GuruFocus
Market Rankings: Is Cybin Inc stock attractive for passive investorsWeekly Stock Summary & Weekly Watchlist for Consistent Profits - moha.gov.vn
Cybin Inc Stock Analysis and ForecastStock Watchlist Updates & Small Investment Growth Plans - earlytimes.in
Cybin Inc. Primary Exchange Listing will Change to (Nasdaq Global Market: HELP) from (NYSE American LLC - marketscreener.com
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
Beyond The Hype: How Cybin’s Deuterated Platform Solves The "Scalability Crisis" In Psychedelic Medicine - Seeking Alpha
Check out Cybin's stock price (HELP) in real time - CNBC
Cybin to rebrand as Helus Pharma and shift US listing to Nasdaq - MSN
Bond Watch: What technical signals suggest for Cybin Inc stockMarket Movement Recap & AI Enhanced Execution Alerts - moha.gov.vn
Cybin (OTCMKTS:CYBN) Stock Price Up 1.2%Here's Why - MarketBeat
Biggest stock movers Wednesday: Vanda Pharmaceuticals and Cybin - MSN
Cybin 2026 Outlook: Clinical Milestones And Cash Position Set Stage For Momentum (CYBN) - Seeking Alpha
Cybin (CYBN) moves to delist common shares from NYSE American via Form 25 - Stock Titan
Cybin price target raised to $48 from $39 at Guggenheim - MSN
Cybin Launches US$100 Million At-the-Market Equity Program - TipRanks
[6-K] CYBIN INC. Current Report (Foreign Issuer) | CYBN SEC FilingForm 6-K - Stock Titan
Biggest stock movers Wednesday: Vanda Pharmaceuticals, Axsome Therapeutics and Cybin - Seeking Alpha
Cybin (CYBN) Initiates $100M At-the-Market Equity Program - GuruFocus
Cybin initiates at-the-market equity program of up to $100 million - MSN
Cybin, Xpeng And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Cybin launches $100 million at-the-market equity program By Investing.com - Investing.com Nigeria
Cybin Sets Up US$100 Million At-the-Market Equity Program With Cantor Fitzgerald - TipRanks
Cybin sets up US$100 million at-the-market equity program with Cantor Fitzgerald - MSN
Cybin (CYBN) Initiates $100 Million At-the-Market Equity Program - GuruFocus
Cybin launches $100 million at-the-market equity program - Investing.com
Cybin stock falls after launching $100 million ATM program By Investing.com - Investing.com South Africa
Cybin stock falls after launching $100 million ATM program - Investing.com India
Cybin Launches $100 Million At-The-Market Equity Program - marketscreener.com
Cybin Initiates At-The-Market Equity Program of up to US$100 Million - Business Wire
Cybin launches US$100 million at-the-market equity program - MSN
Cybin (NYSEAMERICAN:CYBN) Stock Price Up 4.4%Should You Buy? - MarketBeat
Cybin (OTCMKTS:CLXPF) Shares Up 2.2%Here's What Happened - MarketBeat
The New Psychedelics: One Dose, Eight Hours, a Therapist on Standby - Bloomberg.com
Is Cybin Inc. stock attractive after correctionDividend Growth Stocks & Free Unstoppable Trading Performance - Bollywood Helpline
Cybin to Rebrand as Helus Pharma and Shift U.S. Listing to Nasdaq in Early January - TipRanks
Is Cybin Inc. stock gaining market shareQuarterly Market Summary & Daily Stock Trend Reports - Улправда
Is Cybin Inc R7E stock a top hedge fund pickWeekly Market Outlook & Entry and Exit Point Strategies - moha.gov.vn
Cybin to transfer US stock exchange listing to Nasdaq - MSN
Cybin Inc Stock (CYBN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Cap:
|
Volume (24h):